Clinical outcomes of injectable and conventional pulmonary valve replacement in severe pulmonary regurgitation.
S, T., M, K., A, K., & V, D. (2026). Clinical outcomes of injectable and conventional pulmonary valve replacement in severe pulmonary regurgitation.. Turkish journal of medical sciences. https://doi.org/10.55730/1300-0144.6211
S T, M K, A K, V D. Clinical outcomes of injectable and conventional pulmonary valve replacement in severe pulmonary regurgitation.. Turkish journal of medical sciences. 2026; doi: 10.55730/1300-0144.6211
S T, M K, A K, et al. Clinical outcomes of injectable and conventional pulmonary valve replacement in severe pulmonary regurgitation.[J]. Turkish journal of medical sciences. 2026. DOI: 10.55730/1300-0144.6211.
@article{s2026,
author = {Tak S and Koç M and Kutsal A and Doğan V},
title = {Clinical outcomes of injectable and conventional pulmonary valve replacement in severe pulmonary regurgitation.},
journal = {Turkish journal of medical sciences},
year = {2026},
doi = {10.55730/1300-0144.6211},
note = {PMID: 42499452},
}
TY - JOUR AU - Tak S AU - Koç M AU - Kutsal A AU - Doğan V TI - Clinical outcomes of injectable and conventional pulmonary valve replacement in severe pulmonary regurgitation. T2 - Turkish journal of medical sciences PY - 2026 DO - 10.55730/1300-0144.6211 AN - PMID:42499452 ER -
BACKGROUND/AIM: Pulmonary regurgitation following tetralogy of Fallot repair is a common long-term complication requiring pulmonary valve replacement. Injectable bioprosthetic valves offer a less invasive alternative to conventional surgical replacement, but comparative data in pediatric populations remain limited. This study aimed to evaluate short-term and long-term clinical outcomes of injectable pulmonary valve replacement and conventional pulmonary valve replacement in pediatric patients with severe pulmonary regurgitation following tetralogy of Fallot repair. MATERIALS AND METHODS: This retrospective study included 22 pediatric patients who underwent pulmonary valve replacement. Patients were divided into injectable (n = 9) and conventional (n = 13) groups based on anatomical criteria. Primary outcomes included early postoperative parameters and long-term valve function. The mean follow-up duration was 10.5 ± 2.5 years. RESULTS: Favorable early outcomes were noted in the injectable pulmonary valve replacement cohort, including shorter intensive care unit stay (16.8 ± 6.2 vs. 37.0 ± 23.4 h, p = 0.021), reduced mechanical ventilation duration (5.2 ± 3.9 vs. 15.4 ± 11.4 h, p = 0.019), decreased chest tube drainage (206.7 ± 108.2 vs. 513.1 ± 274.1 mL, p = 0.005), and shorter hospital stay (5.4 ± 2.4 vs. 8.4 ± 3.1 days, p = 0.026). Long-term outcomes indicated similar valve function and right ventricular remodeling in the two groups, with excellent freedom from reintervention (100%) during follow-up. CONCLUSION: Injectable pulmonary valve replacement appears to be a safe alternative, offering favorable early outcomes and long-term valve performance comparable to conventional methods. However, clinical experience and precise patient selection remain critical for achieving optimal results.